100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44HL142389
Award Date
9/1/18
Completion Date
8/31/23
Dollars Obligated
$3.4M
Overview
Activity
10
Transactions
10
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Syntrix Biosystems Inc. (L5Z8K6ZE8LY4)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Auburn, WA 98001, USA
Update #1
Update #2
HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS
Posted 8/24/18
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS - THIS SBIR FAST-TRACK PROPOSAL MEETS THE OBJECTIVES OF NHLBI SMALL BUSINESS TOPIC OF SPECIAL INTEREST FOR FISCAL YEAR 2017 CODE HLS17-04. MYELODYSPLASTIC SYNDROMES (MDS) ARE GENETICALLY AND MORPHOLOGICALLY DIVERSE HEMATOPOIETIC NEOPLASMS THAT ARISE FROM A SMALL POOL OF MUTANT CLONES WITHIN HEMATOPOIETIC STEM AND PROGENITOR COMPARTMENTS. ONLY THREE DRUGS HAVE RECEIVED REGULATORY APPROVAL SPECIFICALLY FOR MDS TREATMENT, ALL WITH SUBOPTIMAL RESPONSE RATES OF
$0
2/28/24
Not listed
HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS - THIS SBIR FAST-TRACK PROPOSAL MEETS THE OBJECTIVES OF NHLBI SMALL BUSINESS TOPIC OF SPECIAL INTEREST FOR FISCAL YEAR 2017 CODE HLS17-04. MYELODYSPLASTIC SYNDROMES (MDS) ARE GENETICALLY AND MORPHOLOGICALLY DIVERSE HEMATOPOIETIC NEOPLASMS THAT ARISE FROM A SMALL POOL OF MUTANT CLONES WITHIN HEMATOPOIETIC STEM AND PROGENITOR COMPARTMENTS. ONLY THREE DRUGS HAVE RECEIVED REGULATORY APPROVAL SPECIFICALLY FOR MDS TREATMENT, ALL WITH SUBOPTIMAL RESPONSE RATES OF
$0
7/28/22
Not listed
HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS - THIS SBIR FAST-TRACK PROPOSAL MEETS THE OBJECTIVES OF NHLBI SMALL BUSINESS TOPIC OF SPECIAL INTEREST FOR FISCAL YEAR 2017 CODE HLS17-04. MYELODYSPLASTIC SYNDROMES (MDS) ARE GENETICALLY AND MORPHOLOGICALLY DIVERSE HEMATOPOIETIC NEOPLASMS THAT ARISE FROM A SMALL POOL OF MUTANT CLONES WITHIN HEMATOPOIETIC STEM AND PROGENITOR COMPARTMENTS. ONLY THREE DRUGS HAVE RECEIVED REGULATORY APPROVAL SPECIFICALLY FOR MDS TREATMENT, ALL WITH SUBOPTIMAL RESPONSE RATES OF
$0
7/28/22
Not listed
HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS - THIS SBIR FAST-TRACK PROPOSAL MEETS THE OBJECTIVES OF NHLBI SMALL BUSINESS TOPIC OF SPECIAL INTEREST FOR FISCAL YEAR 2017 CODE HLS17-04. MYELODYSPLASTIC SYNDROMES (MDS) ARE GENETICALLY AND MORPHOLOGICALLY DIVERSE HEMATOPOIETIC NEOPLASMS THAT ARISE FROM A SMALL POOL OF MUTANT CLONES WITHIN HEMATOPOIETIC STEM AND PROGENITOR COMPARTMENTS. ONLY THREE DRUGS HAVE RECEIVED REGULATORY APPROVAL SPECIFICALLY FOR MDS TREATMENT, ALL WITH SUBOPTIMAL RESPONSE RATES OF
$0
1/28/22
Not listed
HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS - THIS SBIR FAST-TRACK PROPOSAL MEETS THE OBJECTIVES OF NHLBI SMALL BUSINESS TOPIC OF SPECIAL INTEREST FOR FISCAL YEAR 2017 CODE HLS17-04. MYELODYSPLASTIC SYNDROMES (MDS) ARE GENETICALLY AND MORPHOLOGICALLY DIVERSE HEMATOPOIETIC NEOPLASMS THAT ARISE FROM A SMALL POOL OF MUTANT CLONES WITHIN HEMATOPOIETIC STEM AND PROGENITOR COMPARTMENTS. ONLY THREE DRUGS HAVE RECEIVED REGULATORY APPROVAL SPECIFICALLY FOR MDS TREATMENT, ALL WITH SUBOPTIMAL RESPONSE RATES OF
$0
1/28/22